CHE
NEUTRALEarningsChemed Corp
This is the 2026-08-18 snapshot — the signals and analysis for CHE as of this single trading day.
View full CHE research hub →Analysis
Chemed (CHE) is undergoing High-Conviction Price Discovery following a massive Q2 earnings beat, upwardly revised full-year guidance, and a 17% dividend hike announced in early August. The fundamental outperformance, driven largely by 11.9% growth in its VITAS Healthcare segment, has translated directly into a PERFECT_STACK and GOLDEN_CROSS technical setup. With the stock boasting a +2.4% relative strength versus the SPY over the last month, buyers are clearly stepping up to accumulate shares. In the current RISK_ON macro regime where tight credit spreads reflect deep institutional liquidity, CHE's blend of steady cash flow, share buybacks, and dividend growth is being aggressively absorbed despite broader geopolitical headline noise.
Fired Signals
Key Takeaways
- Actionable Thesis: CHE is a high-conviction long, supported by a PERFECT_STACK and GOLDEN_CROSS following a strong Q2 earnings beat, raised guidance, and a 17% dividend hike.
- Key Risk: Weakness in Roto-Rooter's seasonal demand or unexpected regulatory pressure on VITAS Medicare rates could stall momentum.
- What to Watch: Price action relative to the $503.01 line-in-the-sand and continued relative strength versus the broader market.